Private Advisor Group, LLC Intellia Therapeutics, Inc. Transaction History

Private Advisor Group, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 13, 2022	SELL	$38.49 - $76.21 $172,165 - $340,887	-4,473 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$58.27 - $118.99 $243,393 - $497,021	-4,177 Reduced 48.29%	4,473 $325,000
Q4 2021 Feb 10, 2022	SELL	$100.76 - $138.36 $675,293 - $927,288	-6,702 Reduced 43.66%	8,650 $1.02 Million
Q3 2021 Oct 14, 2021	BUY	$132.37 - $176.78 $577,133 - $770,760	4,360 Added 39.67%	15,352 $2.06 Million
Q2 2021 Aug 12, 2021	SELL	$60.88 - $161.91 $265,315 - $705,603	-4,358 Reduced 28.39%	10,992 $1.78 Million
Q1 2021 Apr 22, 2021	BUY	$46.59 - $83.68 $345,977 - $621,407	7,426 Added 93.72%	15,350 $1.23 Million
Q4 2020 Apr 01, 2021	BUY	$18.83 - $63.53 $149,208 - $503,411	7,924 New	7,924 $431,000
Q3 2020 Nov 02, 2020	SELL	$17.47 - $24.93 $8,962 - $12,789	-513 Closed	0 $0
Q2 2020 Aug 17, 2020	BUY	$11.14 - $22.87 $5,714 - $11,732	513 New	513 $11,000

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $775M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Private Advisor Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Private Advisor Group, LLC with notifications on news.